Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension.


Journal

The AAPS journal
ISSN: 1550-7416
Titre abrégé: AAPS J
Pays: United States
ID NLM: 101223209

Informations de publication

Date de publication:
20 05 2019
Historique:
received: 29 10 2018
accepted: 11 04 2019
entrez: 22 5 2019
pubmed: 22 5 2019
medline: 24 3 2020
Statut: epublish

Résumé

Developing mathematical models to predict changes in ocular bioavailability and pharmacokinetics due to differences in the physicochemical properties of complex topical ophthalmic suspension formulations is important in drug product development and regulatory assessment. Herein, we used published FDA clinical pharmacology review data, in-house, and literature rabbit pharmacokinetic data generated for dexamethasone ophthalmic suspensions to demonstrate how the mechanistic Ocular Compartmental Absorption and Transit model by GastroPlus™ can be used to characterize ocular drug pharmacokinetic performance in rabbits for suspension formulations. This model was used to describe the dose-dependent (0.01 to 0.1%) non-linear pharmacokinetic in ocular tissues and characterize the impact of viscosity (1.67 to 72.9 cP) and particle size (5.5 to 22 μm) on in vivo ocular drug absorption and disposition. Parameter sensitivity analysis (hypothetical suspension particle size: 1 to 10 μm, viscosity: 1 to 100 cP) demonstrated that the interplay between formulation properties and physiological clearance through drainage and tear turnover rates in the pre-corneal compartment drives the ocular drug bioavailability. The quick removal of drug suspended particles from the pre-corneal compartment renders the impact of particle size inconsequential relative to viscosity modification. The in vivo ocular absorption is (1) viscosity non-sensitive when the viscosity is high and the impact of viscosity on the pre-corneal residence time reaches the maximum physiological system capacity or (2) viscosity sensitive when the viscosity is below a certain limit. This study reinforces our understanding of the interplay between physiological factors and ophthalmic formulation physicochemical properties and their impact on in vivo ocular drug PK performance in rabbits.

Identifiants

pubmed: 31111305
doi: 10.1208/s12248-019-0334-x
pii: 10.1208/s12248-019-0334-x
doi:

Substances chimiques

Ophthalmic Solutions 0
Suspensions 0
Dexamethasone 7S5I7G3JQL

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

65

Références

J Pharm Sci. 1976 Dec;65(12):1816-22
pubmed: 1032669
J Pharm Pharmacol. 1976 Mar;28(3):210-8
pubmed: 6695
J Pharm Sci. 1975 Aug;64(8):1312-6
pubmed: 1151703
J Pharm Sci. 1998 Dec;87(12):1479-88
pubmed: 10189253
J Pharm Sci. 2019 Jan;108(1):620-629
pubmed: 30385283
Adv Drug Deliv Rev. 2018 Feb 15;126:23-43
pubmed: 29247767
J Pharm Sci. 1979 Apr;68(4):435-43
pubmed: 438963
J Ocul Pharmacol Ther. 2008 Jun;24(3):301-8
pubmed: 18476800
Drug Metab Dispos. 1999 Nov;27(11):1350-9
pubmed: 10534321
J Pharm Sci. 1978 May;67(5):603-6
pubmed: 641790
Eur J Pharm Biopharm. 2015 Sep;95(Pt B):215-26
pubmed: 25603198
Adv Drug Deliv Rev. 2006 Nov 15;58(11):1258-68
pubmed: 17079049
Pharm Res. 2016 Nov;33(11):2680-90
pubmed: 27431864
Drug Metab Dispos. 2015 Nov;43(11):1823-37
pubmed: 26296709
Invest Ophthalmol Vis Sci. 1993 Jun;34(7):2251-9
pubmed: 8505206
J Pharm Sci. 1980 Apr;69(4):391-4
pubmed: 7373531
J Pharm Sci. 1986 Mar;75(3):280-7
pubmed: 3701612
Pharm Res. 2018 May 31;35(8):153
pubmed: 29855726
J Pharmacol Toxicol Methods. 2019 Mar - Apr;96:9-14
pubmed: 30552958
Clin Ophthalmol. 2016 Dec 07;10:2433-2441
pubmed: 27994437
J Pharm Sci. 2012 Aug;101(8):2976-88
pubmed: 22581751
Pharm Res. 1993 Sep;10(9):1308-14
pubmed: 8234168
Eur J Pharm Sci. 2000 May;10(3):195-204
pubmed: 10767597
Mol Pharm. 2017 Aug 7;14(8):2690-2696
pubmed: 28631484
AAPS J. 2016 Jul;18(4):1032-8
pubmed: 27184578

Auteurs

Maxime Le Merdy (M)

Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.

Jianghong Fan (J)

Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA. Jianghong.fan@fda.hhs.gov.

Michael B Bolger (MB)

Simulations Plus, Inc., 42505 10th Street West, Lancaster, California, 93534, USA.

Viera Lukacova (V)

Simulations Plus, Inc., 42505 10th Street West, Lancaster, California, 93534, USA.

Jessica Spires (J)

Simulations Plus, Inc., 42505 10th Street West, Lancaster, California, 93534, USA.

Eleftheria Tsakalozou (E)

Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.

Vikram Patel (V)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.

Lin Xu (L)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.

Sharron Stewart (S)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.

Ashok Chockalingam (A)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.

Suresh Narayanasamy (S)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.

Rodney Rouse (R)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.

Murali Matta (M)

Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.

Andrew Babiskin (A)

Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.

Darby Kozak (D)

Division of Therapeutic Performance, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.

Stephanie Choi (S)

Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.

Lei Zhang (L)

Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.

Robert Lionberger (R)

Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.

Liang Zhao (L)

Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland, 20993, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH